Study Objective: To evaluate the efficacy of reteplase administration in clearing hemodialysis catheters.
Design: Open-label, uncontrolled, observational trial.
Setting: University medical center.
Patients: Thirty-four patients with end-stage renal disease undergoing long-term hemodialysis.
Intervention: Patients had dual-lumen, cuffed, tunneled dialysis catheters placed for long-term vascular access. Reteplase 3 U was instilled into each catheter lumen (total dose 6 U) in the first 20 episodes, 2 U in each catheter lumen (total dose 4 U) in the next 20, and 0.5 U in each catheter lumen (total dose 1 U) in the final 45.
Measurements And Main Results: Over 12 months, 85 episodes of catheter dysfunction were documented. Catheter dysfunction was defined as absence of flow from the catheter lumen, inability to aspirate heparin from the lumen, blood flow rates below 150 ml/minute, or venous pressure greater than 250 mm Hg at blood flow rates below 200 ml/minute. Reteplase was instilled into the catheter lumens and allowed to dwell there until the next hemodialysis session. Successful catheter recanalization was defined as return of aspiration and infusion function allowing dialysis to be completed at blood flow rates above 300 ml/minute. Reteplase restored catheter function in 74 (87%) instances of catheter dysfunction. In the first 40 episodes in which 4- or 6-U doses were given, catheter function was restored in 36 instances (90%). There was no difference in restoration of catheter function between 4 U (18/20, 90%) and 6 U (18/20, 90%). In the last 45 cases in which 1 U was administered, function was restored in 38 catheters (84%). Mean overall dwell times were not different between the first 40 (32 +/- 7 hrs) and the last 45 episodes (33 +/- 10 hrs). The overall mean duration of catheter patency was 45 +/- 39 days. Durations of patency in the three dose groups were not significantly different (44 +/- 38, 46 +/- 40, 45 +/- 39 days). No patient suffered adverse effects related to reteplase.
Conclusion: Reteplase installation in dysfunctional hemodialysis catheters was effective in restoring catheter function in 87% of episodes. A dose of 1 U appears to be as effective as 4 and 6 U.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1592/phco.23.2.137.32086 | DOI Listing |
AME Case Rep
November 2024
Department of General Surgery, the First Affiliated Hospital to Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Background: In general, it is relatively easy to remove peripherally inserted central venous catheter (PICC) by gentle traction without any complications. However, the removal of PICC can be challenging occasionally. If the standard interventions fail to remove the catheter, there are no clear recommendations about what to do.
View Article and Find Full Text PDFEur J Hosp Pharm
January 2025
Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, Utrecht, The Netherlands.
Objectives: Critically ill newborn infants often require simultaneous administration of multiple intravenous (IV) solutions through the same catheter lumen, making compatibility of these solutions crucial in neonatal intensive care units (NICUs). This study aimed to investigate the physical compatibility of insulin aspart, lidocaine, alprostadil and vancomycin with individualised two-in-one parenteral nutrition (PN).
Methods: The study was conducted at the hospital pharmacy's drug compounding facility of the University Medical Centre Utrecht.
Circ Cardiovasc Interv
January 2025
Department of Cardiology, Odense University Hospital, Denmark (K.N.H., J.T., M.N., M.H., J.E.-G., K.T.V., A.J., H.S.H., J.F.L., L.O.J.).
Background: Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported. This study aimed to investigate if lesion preparation with a scoring balloon compared with a standard noncompliant balloon minimizes lumen reduction after implantation of a Magmaris BRS assessed with optical coherence tomography and intravascular ultrasound.
Methods: Eighty-two patients with stable angina were randomized in a ratio of 1:1 to lesion preparation with a scoring balloon versus a standard noncompliant balloon before implantation of a Magmaris BRS.
Catheter Cardiovasc Interv
January 2025
Lancashire Cardiac Centre, Blackpool, UK.
Coronary calcification is a major factor leading to stent under-expansion, and subsequent adverse events. This meta-analysis aimed to evaluate the short and long‑term outcomes of rotational atherectomy (RA), followed by modified balloon (cutting or scoring) (MB) versus plain balloon before drug‑eluting stent implantation for calcified coronary lesions. We searched PubMed, Web of Science (WOS), Scopus, and the Cochrane Library Central Register of Controlled Trials (CENTRAL), from inception until 30 January 2024.
View Article and Find Full Text PDFMediastinum
May 2024
Department of Interventional Radiology, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The mediastinal vasculature can be affected by various etiologies in cancer patients. Both direct and indirect sequela of cancer may result in life-threatening clinical presentations. Tumor growth may cause vessel narrowing and decreased blood flow from either extrinsic mass effect, invasion into the vascular wall, or tumor thrombus within the lumen.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!